Coya Therapeutics (COYA) CMO awarded 140,041 stock options

Rhea-AI Filing Summary

Coya Therapeutics, Inc. reported that Chief Medical Officer Fred Grossman received a grant of stock options to purchase 140,041 shares of common stock at an exercise price of $4.73 per share. The options were awarded at no cash cost at grant and are held directly. Subject to continuous service, the shares underlying the option vest in monthly installments over the next 36 months. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended effective November 17, 2022.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Grossman Fred

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	140,041	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 140,041 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Fred

(Last) (First) (Middle)

5850 SAN FELIPE ST., SUITE 500

(Street)

HOUSTON TX 77057

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coya Therapeutics, Inc. [ COYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.73	01/22/2026		A		140,041		(1)	01/22/2036	Common Stock, par value $0.0001 per share	140,041	$0.00	140,041	D

Explanation of Responses:

1. Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

	/s/ David Snyder, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Coya Therapeutics (COYA) report in this Form 4?

The company reported that Chief Medical Officer Fred Grossman received a grant of stock options covering 140,041 shares of Coya Therapeutics common stock.

What is the exercise price of the options granted to Coya Therapeutics CMO Fred Grossman?

The stock options granted to Fred Grossman have an exercise price of $4.73 per share for Coya Therapeutics common stock.

How do the 140,041 Coya Therapeutics stock options granted to the CMO vest?

The 140,041 options vest in monthly installments over the next 36 months, subject to Dr. Grossman’s continuous service through each vesting date.

What happens to Fred Grossman’s Coya Therapeutics options in a change of control?

Upon a change in control of Coya Therapeutics, all shares underlying the option will vest and the option will become immediately exercisable under the company’s 2021 Equity Incentive Plan.

How many Coya Therapeutics derivative securities does the CMO hold after this Form 4 transaction?

Following the reported transaction, Chief Medical Officer Fred Grossman beneficially owns 140,041 stock options directly, each representing the right to buy one share of common stock.

Does the Form 4 indicate whether Fred Grossman’s Coya Therapeutics options are held directly or indirectly?

The filing shows that the 140,041 stock options are held with direct (D) ownership by Fred Grossman, with no indirect ownership entity noted.